Aslan Fixed Asset Turnover from 2010 to 2024

ASLN Stock  USD 0.54  0.05  10.20%   
Aslan Pharmaceuticals Fixed Asset Turnover yearly trend continues to be very stable with very little volatility. Fixed Asset Turnover is likely to drop to 21.38. During the period from 2010 to 2024, Aslan Pharmaceuticals Fixed Asset Turnover quarterly data regression pattern had sample variance of  214.35 and median of  29.99. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
41.66
Current Value
21.38
Quarterly Volatility
14.64058181
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aslan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aslan main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 398.2 K or Interest Expense of 5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.78, Dividend Yield of 0.0 or Days Sales Outstanding of 5.7. Aslan financial statements analysis is a perfect complement when working with Aslan Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Aslan Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Aslan Pharmaceuticals Technical models . Check out the analysis of Aslan Pharmaceuticals Correlation against competitors.

Latest Aslan Pharmaceuticals' Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of Aslan Pharmaceuticals Ltd over the last few years. It is Aslan Pharmaceuticals' Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aslan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Pretty Stable
   Fixed Asset Turnover   
       Timeline  

Aslan Fixed Asset Turnover Regression Statistics

Arithmetic Mean28.24
Geometric Mean21.76
Coefficient Of Variation51.84
Mean Deviation10.64
Median29.99
Standard Deviation14.64
Sample Variance214.35
Range42.3721
R-Value0.14
Mean Square Error226.40
R-Squared0.02
Significance0.62
Slope0.45
Total Sum of Squares3,001

Aslan Fixed Asset Turnover History

2024 21.38
2023 41.66
2020 46.29
2017 3.92

About Aslan Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Aslan Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Aslan Pharmaceuticals investors use historical funamental indicators, such as Aslan Pharmaceuticals's Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Although Aslan Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Aslan Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aslan Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aslan Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aslan Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 41.66  21.38 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aslan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aslan Pharmaceuticals' short interest history, or implied volatility extrapolated from Aslan Pharmaceuticals options trading.

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aslan Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aslan Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aslan Pharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aslan Pharmaceuticals Ltd Stock:
Check out the analysis of Aslan Pharmaceuticals Correlation against competitors.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
CEOs Directory
Screen CEOs from public companies around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.75)
Revenue Per Share
0.746
Return On Assets
(0.64)
Return On Equity
(4.27)
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.